IGA NEPHROPATHY (IGAN)
Clinical trials for IGA NEPHROPATHY (IGAN) explained in plain language.
Never miss a new study
Get alerted when new IGA NEPHROPATHY (IGAN) trials appear
Sign up with your email to follow new studies for IGA NEPHROPATHY (IGAN), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New RNA drug aims to quiet overactive immune system in kidney disease
Disease control Recruiting nowThis Phase 2 study tests a drug called ADX-038 in 45 adults with kidney diseases like IgA nephropathy and C3G, which are caused by an overactive complement system (part of the immune system). The drug is an RNA molecule designed to block complement proteins. The study will check …
Matched conditions: IGA NEPHROPATHY (IGAN)
Phase: PHASE2 • Sponsor: ADARx Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 23, 2026 11:56 UTC
-
New pill hopes to tame protein leak in kidney patients
Disease control Recruiting nowThis study tests an experimental drug called EVER001 in 45 adults with three types of kidney disease (FSGS, MCD, or IgA nephropathy) that cause protein leakage in urine. Participants take two capsules twice daily for a year. The goal is to see if the drug safely reduces protein l…
Matched conditions: IGA NEPHROPATHY (IGAN)
Phase: PHASE2 • Sponsor: Everest Medicines (China) Co.,Ltd. • Aim: Disease control
Last updated Jun 22, 2026 12:08 UTC
-
New injection aims to slow kidney damage in IgA nephropathy
Disease control Recruiting nowThis study tests an experimental drug called RG002C0106 in 30 adults with IgA nephropathy, a kidney disease. The goal is to see if the drug safely reduces protein in urine, a sign of kidney damage. Participants receive either the drug or a placebo, and neither they nor their doct…
Matched conditions: IGA NEPHROPATHY (IGAN)
Phase: PHASE2 • Sponsor: Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd. • Aim: Disease control
Last updated Jun 22, 2026 12:07 UTC
-
New hope for kidney patients: early budesonide may slow IgA nephropathy
Disease control Recruiting nowThis study tests whether starting budesonide capsules early can help people with IgA nephropathy, a kidney disease. About 200 adults with recent diagnosis and high protein in urine will take the drug for 12 months. Researchers will measure changes in protein levels and kidney fun…
Matched conditions: IGA NEPHROPATHY (IGAN)
Sponsor: Sichuan Provincial People's Hospital • Aim: Disease control
Last updated Jun 17, 2026 12:09 UTC
-
New kidney drug aims to control IgA nephropathy Long-Term
Disease control Recruiting nowThis study tests the long-term safety and effectiveness of HSK39297 tablets in people with IgA nephropathy, a kidney disease. About 73 adults who completed a prior study will take the drug daily for up to a year, with possible dose increases. The goal is to see if the drug can sa…
Matched conditions: IGA NEPHROPATHY (IGAN)
Phase: PHASE2 • Sponsor: Haisco Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 17, 2026 12:07 UTC
-
New drug aims to slow kidney damage in IgA nephropathy
Disease control Recruiting nowThis study tests an experimental tablet called HSK39297 in 370 adults with IgA nephropathy, a kidney disease. The goal is to see if the drug can reduce protein in the urine and slow down kidney function decline over 36 to 48 weeks. Participants will be randomly assigned to receiv…
Matched conditions: IGA NEPHROPATHY (IGAN)
Phase: PHASE3 • Sponsor: Haisco Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 17, 2026 12:04 UTC
-
Experimental CAR-T therapy targets lupus and kidney disease in new trial
Disease control Recruiting nowThis early-stage study tests a new treatment called QT-219C, which uses specially engineered immune cells (CAR-T cells) to target and destroy faulty B cells that drive autoimmune diseases like lupus, kidney disease, and scleroderma. The treatment is given as a one-time infusion a…
Matched conditions: IGA NEPHROPATHY (IGAN)
Phase: EARLY_PHASE1 • Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Disease control
Last updated Jun 15, 2026 19:03 UTC
-
New hope for kidney patients: avacopan combo trial targets crescentic IgA nephropathy
Disease control Recruiting nowThis study tests whether the drug avacopan, combined with a low-dose steroid, can help people with a severe form of IgA nephropathy (a kidney disease). The goal is to reduce protein in the urine and protect kidney function. About 16 adults with active disease and high risk of wor…
Matched conditions: IGA NEPHROPATHY (IGAN)
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 15, 2026 18:56 UTC
-
Engineered immune cells aim to tame autoimmune diseases
Disease control Recruiting nowThis study tests a new treatment called QT-219CX, which uses specially engineered immune cells (CAR-T cells) to target and calm the overactive immune system in people with autoimmune diseases like lupus, kidney disease, and scleroderma. The treatment is given as a one-time infusi…
Matched conditions: IGA NEPHROPATHY (IGAN)
Phase: EARLY_PHASE1 • Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Disease control
Last updated Jun 11, 2026 12:12 UTC
-
Engineered immune cells take on lupus and kidney disease in new trial
Disease control Recruiting nowThis early-stage study is testing a universal donor CAR T-cell therapy that targets two proteins (CD19 and BCMA) on immune cells that drive autoimmune diseases. The goal is to see if it is safe and can help control conditions like lupus, kidney disease, and vasculitis. About 15 p…
Matched conditions: IGA NEPHROPATHY (IGAN)
Phase: PHASE1 • Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Disease control
Last updated Jun 03, 2026 12:05 UTC
-
800-Patient study aims to uncover best treatments for kidney disease
Knowledge-focused Recruiting nowThis observational study will follow 800 adults with IgA nephropathy, a common kidney disease, to see how well current treatments control protein in the urine and preserve kidney function over 12 months. Researchers want to understand why some patients do not respond to standard …
Matched conditions: IGA NEPHROPATHY (IGAN)
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 23, 2026 11:56 UTC